PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of postmedjPostgraduate Medical JournalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Postgrad Med J. 2003 December; 79(938): 672–680.
PMCID: PMC1742910

Dr William Coley and tumour regression: a place in history or in the future

Abstract

Spontaneous tumour regression has followed bacterial, fungal, viral, and protozoal infections. This phenomenon inspired the development of numerous rudimentary cancer immunotherapies, with a history spanning thousands of years. Coley took advantage of this natural phenomenon, developing a killed bacterial vaccine for cancer in the late 1800s. He observed that inducing a fever was crucial for tumour regression. Unfortunately, at the present time little credence is given to the febrile response in fighting infections—no less cancer.

Rapidly growing tumours contain large numbers of leucocytes. These cells play a part in both defence and repair; however, reparative functions can also support tumour growth. Intratumoural infections may reactivate defensive functions, causing tumour regression.

Can it be a coincidence that this method of immunotherapy has been "rediscovered" repeatedly throughout the centuries? Clearly, Coley's approach to cancer treatment has a place in the past, present, and future. It offers a rare opportunity for the development of a broadly applicable, relatively inexpensive, yet effective treatment for cancer. Even in cases beyond the reach of conventional therapy, there is hope.

Full Text

The Full Text of this article is available as a PDF (247K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Coley WB. II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891 Sep;14(3):199–220. [PubMed]
  • NAUTS HC, FOWLER GA, BOGATKO FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 1953;276:1–103. [PubMed]
  • Thomas-Tikhonenko Andrei, Hunter Christopher A. Infection and cancer: the common vein. Cytokine Growth Factor Rev. 2003 Feb;14(1):67–77. [PubMed]
  • Hoption Cann SA, van Netten JP, van Netten C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002 Feb;58(2):115–119. [PubMed]
  • Starnes CO. Coley's toxins in perspective. Nature. 1992 May 7;357(6373):11–12. [PubMed]
  • Bickels Jacob, Kollender Yehuda, Merinsky Ofer, Meller Isaac. Coley's toxin: historical perspective. Isr Med Assoc J. 2002 Jun;4(6):471–472. [PubMed]
  • Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999 May;5(3):42–47. [PubMed]
  • Jackson R. Saint Peregrine, O.S.M.--the patron saint of cancer patients. Can Med Assoc J. 1974 Oct 19;111(8):824–827. [PMC free article] [PubMed]
  • Ifrah N, James JM, Viguie F, Marie JP, Zittoun R. Spontaneous remission in adult acute leukemia. Cancer. 1985 Sep 1;56(5):1187–1190. [PubMed]
  • Maekawa T, Fujii H, Horiike S, Okuda T, Yokota S, Ueda K, Urata Y. [Spontaneous remission of four months' duration in hypoplastic leukemia with tetraploid chromosome after blood transfusions and infection]. Nihon Ketsueki Gakkai Zasshi. 1989 Aug;52(5):849–857. [PubMed]
  • Sureda M, Subirá ML, Martín Algarra S, Prieto Valtueña J, Sangro B. Regresión tumoral espontánea. A propósito de dos casos. Med Clin (Barc) 1990 Sep 15;95(8):306–308. [PubMed]
  • Rebollo J, Llorente I, Yoldi A. Regresión tumoral espontánea en un paciente con cáncer gástrico metastásico. Communicación de un caso adicional. Rev Med Univ Navarra. 1990 Jul-Sep;34(3):141–142. [PubMed]
  • Fassas A, Sakellari I, Anagnostopoulos A, Saloum R. Spontaneous remission of acute myeloid leukemia in a patient with concurrent Pneumocystis carinii pneumonia. Nouv Rev Fr Hematol. 1991;33(5):363–364. [PubMed]
  • Marcos Sánchez F, Juárez Ucelay F, Bru Espino IM, Durán-Pérez Navarro A. Un nuevo caso de regresión tumoral espontánea. An Med Interna. 1991 Sep;8(9):468–468. [PubMed]
  • Frick S, Frick P. Spontanremissionen bei chronischer lymphatischer Leukämie. Schweiz Med Wochenschr. 1993 Feb 27;123(8):328–334. [PubMed]
  • Delmer A, Heron E, Marie JP, Zittoun R. Spontaneous remission in acute myeloid leukaemia. Br J Haematol. 1994 Aug;87(4):880–882. [PubMed]
  • García-Rayo S, Gúrpide A, Vega F, Brugarolas A. Regresión tumoral espontánea en un paciente con mieloma múltiple. Comunicación de un caso adicional. Rev Med Univ Navarra. 1996 Jul-Sep;40(3):41–42. [PubMed]
  • Mitterbauer M, Fritzer-Szekeres M, Mitterbauer G, Simonitsch I, Knöbl P, Rintelen C, Schwarzinger I, Haas OA, Silberbauer K, Frey K, et al. Spontaneous remission of acute myeloid leukemia after infection and blood transfusion associated with hypergammaglobulinaemia. Ann Hematol. 1996 Oct;73(4):189–193. [PubMed]
  • Bowles AP, Jr, Perkins E. Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. Neurosurgery. 1999 Mar;44(3):636–643. [PubMed]
  • Tzankov A, Ludescher C, Duba HC, Steinlechner M, Knapp R, Schmid T, Grünewald K, Gastl G, Stauder R. Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. Ann Hematol. 2001 Jul;80(7):423–425. [PubMed]
  • Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972 Nov 16;287(20):1013–1017. [PubMed]
  • Isaacs SN, Axelrod PI, Lorber B. Antipyretic orders in a university hospital. Am J Med. 1990 Jan;88(1):31–35. [PubMed]
  • Thomas V, Riegel B, Andrea J, Murray P, Gerhart A, Gocka I. National survey of pediatric fever management practices among emergency department nurses. J Emerg Nurs. 1994 Dec;20(6):505–510. [PubMed]
  • Bonadio WA, Romine K, Gyuro J. Relationship of fever magnitude to rate of serious bacterial infections in neonates. J Pediatr. 1990 May;116(5):733–735. [PubMed]
  • Mackowiak PA, Wasserman SS, Levine MM. An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. J Infect Dis. 1992 Nov;166(5):1181–1184. [PubMed]
  • Mackowiak PA, Wasserman SS, Tacket CO, Vaughn DW, Eckels KH, Dubois DR, Hoke CH, Edelman R. Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines. Clin Infect Dis. 1994 Nov;19(5):948–950. [PubMed]
  • Bryant RE, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed]
  • Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis. 1983 Jan-Feb;5(1):54–70. [PubMed]
  • Roghmann MC, Warner J, Mackowiak PA. The relationship between age and fever magnitude. Am J Med Sci. 2001 Aug;322(2):68–70. [PubMed]
  • Whitrow M. Wagner-Jauregg and fever therapy. Med Hist. 1990 Jul;34(3):294–310. [PMC free article] [PubMed]
  • Chernin E. The malariatherapy of neurosyphilis. J Parasitol. 1984 Oct;70(5):611–617. [PubMed]
  • Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001 Jan-Feb;17(1):1–18. [PubMed]
  • Aubert A. Sickness and behaviour in animals: a motivational perspective. Neurosci Biobehav Rev. 1999 Nov;23(7):1029–1036. [PubMed]
  • Hasday JD, Fairchild KD, Shanholtz C. The role of fever in the infected host. Microbes Infect. 2000 Dec;2(15):1891–1904. [PubMed]
  • Baracos VE, Whitmore WT, Gale R. The metabolic cost of fever. Can J Physiol Pharmacol. 1987 Jun;65(6):1248–1254. [PubMed]
  • Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988 Summer;12(2):123–137. [PubMed]
  • Toms GL, Davies JA, Woodward CG, Sweet C, Smith H. The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence. Br J Exp Pathol. 1977 Aug;58(4):444–458. [PubMed]
  • Vaughn LK, Veale WL, Cooper KE. Antipyresis: its effect on mortality rate of bacterially infected rabbits. Brain Res Bull. 1980 Jan-Feb;5(1):69–73. [PubMed]
  • Vaughn LK, Veale WL, Cooper KE. Effects of antipyresis on bacterial numbers in infected rabbits. Brain Res Bull. 1981 Aug;7(2):175–180. [PubMed]
  • Husseini RH, Sweet C, Collie MH, Smith H. Elevation of nasal viral levels by suppression of fever in ferrets infected with influenza viruses of differing virulence. J Infect Dis. 1982 Apr;145(4):520–524. [PubMed]
  • Dwinger RH, Vos J, Nieuwenhuijs J, Zwart D, van Miert AS. Studies on the influence of non-steroidal anti-inflammatory drugs upon trypanosomiasis in goats and sheep. J Vet Pharmacol Ther. 1984 Dec;7(4):293–301. [PubMed]
  • Esposito AL. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis. 1984 Nov;130(5):857–862. [PubMed]
  • Kurosawa S, Kobune F, Okuyama K, Sugiura A. Effects of antipyretics in rinderpest virus infection in rabbits. J Infect Dis. 1987 May;155(5):991–997. [PubMed]
  • Crocker JF, Digout SC, Lee SH, Rozee KR, Renton K, Field CA, Acott P, Murphy MG. Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome. Clin Invest Med. 1998 Aug-Oct;21(4-5):192–202. [PubMed]
  • Brandts CH, Ndjavé M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet. 1997 Sep 6;350(9079):704–709. [PubMed]
  • Doran TF, De Angelis C, Baumgardner RA, Mellits ED. Acetaminophen: more harm than good for chickenpox? J Pediatr. 1989 Jun;114(6):1045–1048. [PubMed]
  • Sugimura T, Fujimoto T, Motoyama H, Maruoka T, Korematu S, Asakuno Y, Hayakawa H. Risks of antipyretics in young children with fever due to infectious disease. Acta Paediatr Jpn. 1994 Aug;36(4):375–378. [PubMed]
  • Graham NM, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis. 1990 Dec;162(6):1277–1282. [PubMed]
  • Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V. Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA. 1975 Mar 24;231(12):1248–1251. [PubMed]
  • Plaisance KI, Kudaravalli S, Wasserman SS, Levine MM, Mackowiak PA. Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections. Pharmacotherapy. 2000 Dec;20(12):1417–1422. [PubMed]
  • Rietveld JA, Pilmore HL, Jones PG, Theis JC, Bowie DA, Dempster AG, Walker RJ. Necrotising fasciitis: a single centre's experience. N Z Med J. 1995 Mar 8;108(995):72–74. [PubMed]
  • Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics. 1999 Apr;103(4 Pt 1):783–790. [PubMed]
  • Barnham MRD, Weightman NC, Anderson AW, Tanna A. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect. 2002 Mar;8(3):174–181. [PubMed]
  • Byington Carrie L, Spencer LaShonda Y, Johnson Timothy A, Pavia Andrew T, Allen Daniel, Mason Edward O, Kaplan Sheldon, Carroll Karen C, Daly Judy A, Christenson John C, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002 Feb 15;34(4):434–440. [PubMed]
  • Old LJ. Tumor necrosis factor. Sci Am. 1988 May;258(5):59–75. [PubMed]
  • Nethersell AB. Biological modifiers and their role in cancer therapy. Ann Acad Med Singapore. 1990 Mar;19(2):223–234. [PubMed]
  • Oettgen HF. Biological agents in cancer therapy: cytokines, monoclonal antibodies and vaccines. J Cancer Res Clin Oncol. 1990;116(1):116–119. [PubMed]
  • Bassi PierFrancesco. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol. 2002 Jun;11(1-2):77–83. [PubMed]
  • Viallard JF, Denis D, Texier-Maugein J, Parrens M, Faure I, Pellegrin JL, Leng B. Disseminated infection after bacille Calmette-Guérin instillation for treatment of bladder carcinoma. Clin Infect Dis. 1999 Aug;29(2):451–452. [PubMed]
  • Göttke MU, Wong P, Muhn C, Jabbari M, Morin S. Hepatitis in disseminated bacillus Calmette-Guérin infection. Can J Gastroenterol. 2000 Apr;14(4):333–336. [PubMed]
  • Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan;169(1):90–95. [PubMed]
  • Fleischmann JD, Toossi Z, Ellner JJ, Wentworth DB, Ratliff TL, Imbembo AL. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer. 1989 Oct 1;64(7):1447–1454. [PubMed]
  • Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol. 1990 Jul;144(1):59–64. [PubMed]
  • de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res. 1997;25(1):31–34. [PubMed]
  • Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology. 1998 Aug;52(2):268–276. [PubMed]
  • Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, Saito Y. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol. 1999 Jan;115(1):131–135. [PubMed]
  • Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol. 2000 Dec;164(6):2129–2133. [PubMed]
  • Watanabe Etsuya, Matsuyama Hideyasu, Matsuda Kenji, Ohmi Chietaka, Tei Yasuhide, Yoshihiro Satoru, Ohmoto Yasukazu, Naito Katsusuke. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003 Aug;52(8):481–486. [PubMed]
  • Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996 Oct;9(4):532–562. [PMC free article] [PubMed]
  • Molinari JA, Carrick L, Jr, Lubiniecki AS. Influence of Trichinella spiralis infection on development of sarcoma-180 ascites tumors. Tropenmed Parasitol. 1979 Dec;30(4):429–433. [PubMed]
  • Cabral HR. The tumoricidal effect of Trypanosoma cruzi: its intracellular cycle and the immune response of the host. Med Hypotheses. 2000 Jan;54(1):1–6. [PubMed]
  • Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001 Nov;1(2):135–145. [PubMed]
  • Okamoto Masato, Sato Mitsunobu. Toll-like receptor signaling in anti-cancer immunity. J Med Invest. 2003 Feb;50(1-2):9–24. [PubMed]
  • van Netten JP, Ashmed BJ, Cavers D, Fletcher C, Thornton IG, Antonsen BL, Coy P, Brigden ML. 'Macrophages' and their putative significance in human breast cancer. Br J Cancer. 1992 Jul;66(1):220–221. [PMC free article] [PubMed]
  • van Netten JP, George EJ, Ashmead BJ, Fletcher C, Thornton IG, Coy P. Macrophage-tumour cell associations in breast cancer. Lancet. 1993 Oct 2;342(8875):872–873. [PubMed]
  • al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb. 2000 Feb;45(1):1–16. [PubMed]
  • Schoppmann Sebastian F, Birner Peter, Stöckl Johannes, Kalt Romana, Ullrich Robert, Caucig Carola, Kriehuber Ernst, Nagy Katalin, Alitalo Kari, Kerjaschki Dontscho. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002 Sep;161(3):947–956. [PubMed]
  • van Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher C, Cavers D, Coy P, Brigden ML. Macrophage-tumor cell associations: a factor in metastasis of breast cancer? J Leukoc Biol. 1993 Oct;54(4):360–362. [PubMed]
  • Whalen GF. Solid tumours and wounds: transformed cells misunderstood as injured tissue? Lancet. 1990 Dec 15;336(8729):1489–1492. [PubMed]
  • van Netten JP, Mogentale T, Smith MJ, Fletcher C, Coy P. Physical trauma and breast cancer. Lancet. 1994 Apr 16;343(8903):978–979. [PubMed]
  • Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, Strasser RH, Daniel WG. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001 Feb 16;49(3):671–680. [PubMed]
  • Rehman Jalees, Li Jingling, Orschell Christie M, March Keith L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003 Mar 4;107(8):1164–1169. [PubMed]
  • Adams EF, Newton CJ, Braunsberg H, Shaikh N, Ghilchik M, James VH. Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Res Treat. 1988 May;11(2):165–172. [PubMed]
  • Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000 Apr;156(4):1363–1380. [PubMed]
  • Barbera-Guillem Emilio, Nyhus Julie K, Wolford Chris C, Friece Chad R, Sampsel James W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002 Dec 1;62(23):7042–7049. [PubMed]
  • Kataki Agapi, Scheid Philippe, Piet Maud, Marie Beatrice, Martinet Nadine, Martinet Yves, Vignaud Jean-Michel. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002 Nov;140(5):320–328. [PubMed]
  • Kirkwood John M, Bender Catherine, Agarwala Sanjiv, Tarhini Ahmad, Shipe-Spotloe Janice, Smelko Barbara, Donnelly Sandra, Stover Lori. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 1;20(17):3703–3718. [PubMed]
  • Kluger MJ, Kozak W, Conn CA, Leon LR, Soszynski D. Role of fever in disease. Ann N Y Acad Sci. 1998 Sep 29;856:224–233. [PubMed]
  • Mayfield KP, Kozak A, Rudolph K, Kluger MJ. Morphine suppresses development of fever to lipopolysaccharide in rats. Ann N Y Acad Sci. 1998 Sep 29;856:281–285. [PubMed]
  • Wei Gang, Moss Jonathan, Yuan Chun Su. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol. 2003 Jun 1;65(11):1761–1766. [PubMed]
  • Lax Alistair J, Thomas Warren. How bacteria could cause cancer: one step at a time. Trends Microbiol. 2002 Jun;10(6):293–299. [PubMed]
  • Honkoop AH, Kaan JA, van de Stadt J, ten Napel CH. Een man met spontane regressie van non-Hodgkin-lymfoom, hypergammaglobulinemie en infectie met twee herpes-virussen; causaliteit of coïncidentie? Ned Tijdschr Geneeskd. 1993 Apr 10;137(15):774–777. [PubMed]
  • SENSENIG DM, ROSSI NP, EHRENHAFT JL. Results of the surgical treatment of bronchogenic carcinoma. Surg Gynecol Obstet. 1963 Mar;116:279–284. [PubMed]
  • Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1970 May;59(5):642–644. [PubMed]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group